NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis $2.38 -0.06 (-2.26%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sana Biotechnology Stock (NASDAQ:SANA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sana Biotechnology alerts:Sign Up Key Stats Today's Range$2.37▼$2.4550-Day Range$2.27▼$3.9252-Week Range$2.22▼$5.49Volume525,752 shsAverage Volume3.16 million shsMarket Capitalization$711.65 millionP/E RatioN/ADividend YieldN/APrice Target$9.60Consensus RatingModerate Buy Company Overview Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes. These are investigational programs, not approved products. Sana conducts research and development in the United States, with locations including Seattle, South San Francisco and Cambridge. Its chief executive officer is Steve Harr.AI Generated. May Contain Errors. Read More Sana Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreSANA MarketRank™: 2.95741324921 of 5 starsSana Biotechnology scored higher than 59% of companies evaluated by MarketBeat, and ranked 402nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSana Biotechnology has a consensus price target of $9.60, representing about 304.2% upside from its current price of $2.38.Amount of Analyst CoverageSana Biotechnology has only been the subject of 3 research reports in the past 90 days.Read more about Sana Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($0.62) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.16% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 15.77, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently decreased by 0.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.91 News SentimentSana Biotechnology has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sana Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SANA Stock News HeadlinesSana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical TrialsNovember 6, 2026 | rttnews.comSana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. After that, only about 78% of scheduled benefits can be paid unless Congress acts. Higher taxes, smaller checks or more borrowing are all on the table. The morning after Democrats took Congress, gold jumped almost 3% and silver jumped 4%. If you count on Social Security for any part of your retirement, a backup plan matters before 2032.November 11 at 1:00 AM | Priority Gold (Ad)Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business UpdatesNovember 5, 2026 | markets.businessinsider.comSana Biotechnology, Inc. (SANA) Analyst Insights, Price Targets & Recommendations - Yahoo FinanceNovember 3, 2026 | finance.yahoo.comSana Biotechnology: A Shot At DiabetesOctober 13, 2026 | seekingalpha.com6 'moonshot' biotech stocks that offer big risks, bigger rewardsSeptember 23, 2026 | msn.comSana Biotechnology (SANA)September 23, 2026 | es.investing.comSee More Headlines SANA Stock Analysis - Frequently Asked Questions How have SANA shares performed this year? Sana Biotechnology's stock was trading at $4.07 at the beginning of 2026. Since then, SANA shares have decreased by 41.6% and is now trading at $2.3750. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $552 million in an IPO on Wednesday, February 3rd 2021. The company issued 23,500,000 shares at $23.00-$24.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's top institutional investors include Russell Investments Group Ltd. (0.05%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.03%), Profund Advisors LLC (0.03%) and Ieq Capital LLC (0.02%). Insiders that own company stock include Robert Nelsen, Fmr Llc and Richard Mulligan. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Micron Technology (MU), Archer Aviation (ACHR), Advanced Micro Devices (AMD), D-Wave Quantum (QBTS) and SoFi Technologies (SOFI). Company Calendar Last Earnings11/05/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SANA's financial health is in the Yellow zone, according to TradeSmith. SANA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SANA CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees142Year Founded2018Price Target and Rating Average Price Target for Sana Biotechnology$9.60 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+302.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$244.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.10% Return on Assets-41.60% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book3.98Miscellaneous Outstanding Shares299,640,000Free Float223,528,000Market Cap$714.64 million OptionableOptionable Beta2.30 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:SANA) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored55+? Elon’s Gift…James Altucher points to Elon Musk's latest FCC filing as a potential turning point for retirees relying on So...Paradigm Press | SponsoredSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. Af...Priority Gold | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
